Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05042206
Other study ID # PMC-P-12
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 24, 2021
Est. completion date September 21, 2023

Study information

Verified date March 2024
Source Pharmicell Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease. The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.


Description:

The screening test is performed after the clinical trial subject consents in writing to participate in the clinical trial. Subjects who meet the inclusion/exclusion criteria are registered in the clinical trial, and Cellgram-CKD is injected intravenously by puncturing a vein with a needle. After injecting Cellgram-CKD three times at an interval of 2 weeks (14 days), the subject visits the testing institution at 1 month, 3 months, 6 months, 9 months and 12 months for safety evaluation. However, since the safety of Cellgram-CKD has not been established, proceed as follows. In the first 3 subjects who received the investigational product, if no adverse events of Grade 3 or higher according to the NCI-CTCAE related to the investigational product occur 14 days after the 1st and 2nd administration, and 1 month after the 3rd administration, the remaining subjects were sequentially treated. Register as a member and conduct clinical trials. If an adverse event of Grade 3 or higher according to the NCI-CTCAE standard related to the test drug occurs in two of the first three subjects, the clinical trial is terminated early. is conducted by registering three additional test subjects in the same way as the first. If one or more of the three subjects develops a Grade 3 or higher adverse event related to the investigational product, the clinical trial is terminated early, and the remaining subjects are treated only if all three subjects do not have a Grade 3 or higher adverse reaction related to the investigational product. Register to continue the clinical trial.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date September 21, 2023
Est. primary completion date September 21, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years to 79 Years
Eligibility Inclusion Criteria: - Male or female between the ages of 19 and 79 - Those diagnosed with CKD stage 3b or 4 [eGFR 15 - 44 ml/min/1.73 m2] within 1 year before screening - Those who voluntarily participated in the clinical trial and signed the Informed consent form Exclusion Criteria: - Those with severe cardiovascular disease (angina, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit - Those with the following medical history/comorbidities A. Gentamicin hypersensitivity reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. Clinically significant cognitive disorder, dementia or psychiatric disorder D. Alcohol or drug abuse E. Severe respiratory disease (COPD, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) F. Stroke G. Systemic autoimmune disease - Those whose test results fall under the following at the screening visit A. Pathogenic microorganism test (Hbs Ag, HCV Ab, HIV Ab, Syphilis) positive B. Uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg) C. AST and ALT = upper limit of normal x 3.0 D. Total bilirubin = upper limit of normal x 1.5 - At screening, those who have the following treatment history A. Those who are being treated for severe systemic infection B. Those who have been treated with immunosuppressant within 28 days prior to screening - Those with a history of renal transplantation - Those who have received dialysis within 3 months prior to the screening visit or who are planning to undergo dialysis during the clinical trial period - Pregnant, lactating, or planning during clinical trials - Those who do not agree to comply with the contraceptive method specified in this protocol during the clinical trial period - Those who are receiving drugs that are expected to affect the results of this clinical trial when judged by the investigator - Those who participated in other interventional clinical trials within 4 weeks prior to the screening visit and received investigational products/medical devices for investigational use or received procedures - Those who have or are planning to administer other cell therapy products - Those who are judged by the investigator to be inappropriate to participate in this clinical trial

Study Design


Intervention

Biological:
Cellgram-CKD
Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Pharmicell Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0) The primary endpoint is an adverse event, and the level of the adverse event (AE) is analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0). Adverse events are collected from the first administration of the investigational product to 12 months after the third administration of the investigational product.
Secondary Changes in eGFR Changes in eGFR after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline 1, 3, 6, 9, and 12 months of administration of the investigational product
Secondary Changes in BUN Changes in BUN after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline 1, 3, 6, 9, and 12 months of administration of the investigational product
Secondary Changes in Creatinine Changes in Creatinine after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline 1, 3, 6, 9, and 12 months of administration of the investigational product
See also
  Status Clinical Trial Phase
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Completed NCT03293446 - AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls N/A
Completed NCT04858854 - Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2 N/A
Completed NCT05624840 - Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Recruiting NCT05489120 - Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD) N/A
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Completed NCT05153174 - Study of Sulphoraphane in Chronic Kidney Disease Phase 1/Phase 2
Recruiting NCT03582982 - Flywheel Exercise for CKD N/A
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Not yet recruiting NCT03348839 - Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease N/A
Recruiting NCT04913272 - Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV Phase 2
Recruiting NCT04330807 - Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease N/A
Completed NCT05931978 - Effect of a CKD Dashboard on Patient Activation and Shared Decision Making N/A
Recruiting NCT05543928 - Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism Phase 3
Active, not recruiting NCT06037265 - PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System N/A
Completed NCT04617431 - Application of Wearable Devices to Build a Self-Management Model in Chronic Kidney Disease Patients N/A
Recruiting NCT04336033 - Validation and Evaluation of a Newly Developed Mobile Diet App N/A
Recruiting NCT05138419 - A Pragmatic Approach to CKD Patient Education N/A
Not yet recruiting NCT06394544 - Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment N/A
Recruiting NCT01410617 - The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass Phase 2/Phase 3